Literature DB >> 29048517

Vertebral Compression Fracture After Spine Stereotactic Body Radiation Therapy: A Review of the Pathophysiology and Risk Factors.

Salman Faruqi1, Chia-Lin Tseng1, Cari Whyne2, Majed Alghamdi1, Jefferson Wilson3, Sten Myrehaug1, Hany Soliman1, Young Lee1, Pejman Maralani4, Victor Yang5, Charles Fisher6, Arjun Sahgal1.   

Abstract

BACKGROUND: Vertebral compression fracture (VCF) is a challenging and not infrequent complication observed following spine stereotactic body radiation therapy (SBRT).
OBJECTIVE: To summarize the data from the multiple studies that have been published, addressing the risk and predictive factors for VCF post-SBRT.
METHODS: A systematic literature review was conducted. Studies were selected if they specifically addressed risk factors for post-SBRT VCF in their analyses.
RESULTS: A total of 11 studies were identified, reporting both the risk of VCF post-SBRT and an analysis of risk factors based on univariate and multivariate analysis. A total of 2911 spinal segments were treated with a crude VCF rate of 13.9%. The most frequently identified risk factors on multivariate analysis were: lytic disease (hazard ratio [HR] range, 2.76-12.2), baseline VCF prior to SBRT (HR range, 1.69-9.25), higher dose per fraction SBRT (HR range, 5.03-6.82), spinal deformity (HR range, 2.99-11.1), older age (HR range, 2.15-5.67), and more than 40% to 50% of vertebral body involved by tumor (HR range, 3.9-4.46). In the 9 studies that specifically reported on the use of post-SBRT surgical procedures, 37% of VCF had undergone an intervention (range, 11%-60%).
CONCLUSION: VCF is an important adverse effect following SBRT. Risk factors have been identified to guide the selection of high-risk patients. Evidence-based algorithms with respect to patient selection and intervention are needed.

Entities:  

Mesh:

Year:  2018        PMID: 29048517     DOI: 10.1093/neuros/nyx493

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  21 in total

Review 1.  Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: Classification into five treatment groups.

Authors:  Kei Ito; Naoki Nakamura; Takuya Shimizuguchi; Hiroaki Ogawa; Katsuyuki Karasawa
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-18

Review 2.  Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review.

Authors:  Valentina Lancellotta; Giuseppe Fanetti; Fabio Monari; Monica Mangoni; Renzo Mazzarotto; Luca Tagliaferri; Carlo Gobitti; Elisa Lodi Rizzini; Sara Talomo; Irene Turturici; Fabiola Paiar; Renzo Corvò; Barbara Alicja Jereczek-Fossa; Vittorio Donato; Federica Vianello
Journal:  Radiol Med       Date:  2022-04-08       Impact factor: 3.469

3.  Stereotactic ablative radiation therapy for spinal metastases: experience at a single Brazilian institution.

Authors:  Gustavo N Marta; Fernando F de Arruda; Fabiana A Miranda; Alice R N S Silva; Wellington F P Neves-Junior; Anselmo Mancini; Samir A Hanna; Carlos E C V Abreu; João Luis F da Silva; Jose Eduardo V Nascimento; Cecília Maria K Haddad; Fabio Y Moraes; Rafael Gadia
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

4.  Appropriate Patient Status for Ra-223 Treatment in the Treatment Sequence for Castration-resistant Prostate Cancer.

Authors:  Hitoshi Ito; Hiroshi Yaegashi; Yoshiyuki Okada; Takafumi Shimada; Toshihide Yamaoka; Kazutoshi Okubo; Takashi Sakamoto; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2022-07-03

5.  Highlights on the Management of Oligometastatic Disease.

Authors:  Salem M Alshehri; Khaled Alkattan; Ahmed Abdelwarith; Hussain Alhussain; Shaker Shaker; Majed Alghamdi; Hossam Alassaf; Ali Albargawi; Manal Al Naimi; Ameen Alomair; Saif Althaqfi; Adnan Alhebshi; Majid Alothman; AbdulRahman Jazieh
Journal:  J Immunother Precis Oncol       Date:  2020-02-05

6.  [Single dose of 24 Gy or 3-fraction SBRT regimen in the treatment of oligometastatic cancer? : A phase III multi-center trial].

Authors:  Hossein Hemmatazad; Etienne Mathier; Daniel M Aebersold; Mohamed Shelan
Journal:  Strahlenther Onkol       Date:  2021-06-29       Impact factor: 3.621

7.  Conventional finite element models estimate the strength of metastatic human vertebrae despite alterations of the bone's tissue and structure.

Authors:  Marc A Stadelmann; Denis E Schenk; Ghislain Maquer; Christopher Lenherr; Florian M Buck; Dieter D Bosshardt; Sven Hoppe; Nicolas Theumann; Ron N Alkalay; Philippe K Zysset
Journal:  Bone       Date:  2020-08-20       Impact factor: 4.626

8.  A phase III randomized-controlled, single-blind trial to improve quality of life with stereotactic body radiotherapy for patients with painful bone metastases (ROBOMET).

Authors:  Carole Mercier; Piet Dirix; Piet Ost; Charlotte Billiet; Ines Joye; Peter Vermeulen; Yolande Lievens; Dirk Verellen
Journal:  BMC Cancer       Date:  2019-09-04       Impact factor: 4.430

Review 9.  Radium-223 mechanism of action: implications for use in treatment combinations.

Authors:  Michael J Morris; Eva Corey; Theresa A Guise; James L Gulley; William Kevin Kelly; David I Quinn; Arne Scholz; George Sgouros
Journal:  Nat Rev Urol       Date:  2019-11-11       Impact factor: 14.432

10.  Stereotactic Spinal Radiosurgery and Delayed Vertebral Fracture Risk.

Authors:  Jaden D Evans; Paul D Brown; Kenneth R Olivier
Journal:  Adv Radiat Oncol       Date:  2018-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.